Frequent promoter methylation of M-cadherin in hepatocellular carcinoma is associated with poor prognosis

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2269-2274

  Yamada, Suguru ^a   Nomoto, Shuji ^a   Fujii, Tsutomu ^a   Takeda, Shin ^a   Kanazumi, Naohito ^a   Sugimoto, Hiroyuki ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

Cadherin; Hepatocellular carcinoma; Methylation; Prognosis

Indexed keywords

CADHERIN; M CADHERIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GENE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LIVER; LIVER CELL CARCINOMA; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION;

ADULT; AGED; CADHERINS; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER;

EID: 34547738046     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Parkin DM, Bray F and Ferlay J: Global Cancer Statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
3. Merlo A, Herman JG and Mao L: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
4. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440, 2002.
5. Tokumaru Y, Nomoto S and Jeronimo C: Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene 22: 6954-6958, 2003.
6. Laurent-Puig P, Legoix P and Bluteau O: Genetic alterations with hepatocellular carcinoma define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773, 2001.
7. de La Coste A, Romagnolo B and Billuart P: Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95: 8847-8851, 1998.
8. Satoh S, Daigo Y and Furukawa Y: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24: 245-250, 2000.
9. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science (Washington DC) 251: 1451-1455, 1991.
10. Levenberg S, Yarden A and Kam Z: p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene 18: 869-876, 1999.
11. Kadowaki T, Shiozaki H and Inoue M: E-cadherin and α-catenin expression in human esophageal cancer. Cancer Res 54: 291-296, 1994.
12. Guilford P, Hopkins J and Harraway J: E-cadherin germline mutations in familial gastric cancer. Nature 392: 402-405, 1998.
13. Efstathiou JA, Liu D and Wheeler JMD: Mutated E cadherin is associated with increased tumorigenicity, loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci USA 96: 2316-2321, 1999.
14. Kozyraki R, Scoazec JY and Flejou JF: Expression of cadherins and a-catenin in primary epithelial tumors of the liver. Gastroenterology 110: 1137-1149, 1996.
15. Pignatelli M, Ansari TW and Gunter P: Loss of membranous E-cadherin expression in pancreatic cancer. Correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 174: 243-248, 1994.
16. Sulzer MA, Leers MP and van Noord JA: Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Resp Crit Care 157: 1319-1323, 1998.
17. Graff JR, Herman JG and Lapidus RG: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195-5199, 1995.
18. Hazan RB, Kang L and Whooley BP: N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun 4: 399-411, 1997.
19. Pishvarian MJ, Feltes CM and Thompson P: Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 59: 947-952, 1999.
20. Toyooka KO, Toyooka S and Virmani AK: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61: 4556-4560, 2001.
21. Yoshimura K, Kanai Y and Ochiai A: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416-7419, 1995.
22. Tsuda H, Zhang WD and Shimosato Y: Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6791-6794, 1990.
23. Yakicier MC, Legoix P and Vaury C: Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma. Oncogene 20: 5232-5238, 2001.
24. Ihara A, Koizumi H and Hashizume R: Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinoma. Hepatology 23: 1441-1447, 1996.
25. Kanai Y, Ushijima AM and Ochiai A: The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinoma. Int J Cancer 71: 355-359, 1997.
26. Matsumura T, Makino R and Mitamura K: Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinoma. Clin Cancer Res 7: 594-599, 2001.
27. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 4th ed. Tokyo, Kanehara, 2000.
28. Donalies M, Cramer M and Ringwald M: Expression of M-cadherin, a member of the cadherin multigene family, correlates with differentiation of skeletal muscle cells. Proc Natl Acad Sci USA 88: 8024-8028, 1991.